A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

NCT05560646 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

354

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometriosis

Interventions

DRUG: OG-6219
DRUG: Placebo

Sponsor

Organon and Co

Collaborators

[object Object]